天士力：关于获得药物临床试验批准通知书的公告

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors [1] Group 1 - The approval notification for TSL2109 capsules marks a significant step in the company's research and development efforts in oncology [1] - This development indicates the company's commitment to expanding its product pipeline in the cancer treatment sector [1]